Parkinson’s Disease Science
HT-6283: Investigating Neuroinflammation in Parkinson’s Disease Targeting Inflammation in Neurodegenerative Diseases
HT-6283: Investigating Neuroinflammation in Parkinson’s Disease
Targeting Inflammation in Neurodegenerative Diseases
Parkinson’s disease (PD) is a neurodegenerative disorder associated with motor dysfunction and inflammation. 20 HT-6283, an investigational NLRP3 inhibitor, is being studied for its potential to modulate neuroinflammation in PD. 21 Preclinical research suggests inhibiting NLRP3 may reduce neuroinflammatory cytokine production and potentially slow disease progression. However, further research is required to confirm these findings. 22,23Investigational Status: HT-6283 is an investigational drug and is not currently approved for the treatment of Parkinson’s disease. Further studies are needed to determine its potential activity in this disorder.Obesity
Almost half of US adults are obese or severely obese. Lack of physical activity, unhealthy eating behavior, and, in some cases, genetics contribute to obesity. Halia is developing investigational treatments to combat obesity.
Pain and Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is an autoimmune condition where the immune system—normally the body's defender against infection and disease—attacks its own tissues. This results in pain, swelling, stiffness, and loss of joint function. Halia is developing an investigational treatment for both RA and post-surgical pain.
Alzheimer's Disease
Alzheimer’s disease involves parts of the brain that control memory, language, problem-solving, and other thinking abilities. It can seriously affect a person’s ability to carry out daily activities. Halia is developing a potentially relevant pathway and investigational treatment for Alzheimer’s.
Parkinson's Disease
Parkinson’s disease is a progressive disorder that affects the nervous system and the parts of the body controlled by the nerves. Tremors, stiffness, or slowing of movement are typical symptoms. Halia is developing a potential brain-penetrant compound to treat the disease.